[PMC free article] [PubMed] [Google Scholar] 48. Brechbiel MW, et al..Lead(II) complexes of 1 1,4,7,10-tetraazacyclododecane-N,N,N,N?-tetraacetate: remedy chemistry and software to tumor localization with 203Pb labeled monoclonal antibodies. Inorg Chim Acta. 1995;239:43C51. [Google Scholar] 33. Yong K, Brechbiel MW. Towards translation of 212Pb like a medical therapeutic: getting the lead in! Dalton Trans. 2011;40:6068C6076. [PMC free article] [PubMed] [Google Scholar] 34. Su FM, Beaumier P, Axworthy D, Atcher R, Fritzberg A. Pretargeted radioimmunotherapy in tumored mice using an in?vivo 212Pb/212Bi generator. Nucl Med Biol. 2005;32:741C747. [PubMed] [Google Scholar] 35. Miao Y, Hylarides M, Fisher DR, et al..Melanoma therapy via peptide-targeted -radiation. Clin Malignancy Res. 2005;11:5616C5621. [PubMed] [Google Scholar] 36. Ruble G, Chuanchu W, Squire RA, Gansow OA, Strand M. The use of 212Pb-labeled AZD3839 free base monoclonal antibody in the treatment of murine erythroleukemia. Int J Radiat Oncol Biol Phys. 1996;34:609C616. [PubMed] [Google Scholar] 37. Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, AZD3839 free base Brechbiel MW. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol. 2000;27:93C100. [PubMed] [Google Scholar] 38. Tan Z, Chen P, Schneider N, et al..Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human being prostate cancer in mice. Int J Oncol. 2012;40:1881C1888. Rabbit Polyclonal to CARD11 [PubMed] [Google Scholar] 39. Meredith RF, Torgue JJ, Rozgaja TA, et al..Security and end result actions of first-in-human intraperitoneal radioimmunotherapy with 212Pb-TCMC-trastuzumab. Am J Clin Oncol. 2018;41:716C721. [PMC free article] [PubMed] [Google Scholar] 40. Banerjee SR, Minn I, Kumar V, et al..Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2020;61:80C88. [PMC free article] [PubMed] [Google Scholar] 41. Stenberg VY, Larsen RH, Ma L-W, et al..Evaluation of the PSMA-binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate malignancy. Int J Mol Sci. 2021;22:4815. [PMC free article] [PubMed] [Google Scholar] 42. Kasten BB, Arend RC, Katre AA, et al..B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol. 2017;47:23C30. [PMC free article] [PubMed] [Google Scholar] 43. McNeil BL, Robertson AKH, Fu W, et al..Production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair. EJNMMI Radiopharm Chem. 2021;6:6. [PMC free article] [PubMed] [Google Scholar] 44. Bauer D, Blumberg M, K?ckerling M, Mamat C. A comparative evaluation of calix[4]arene-1,3-crown-6 as a ligand for selected divalent cations of radiopharmaceutical interest. RSC Improvements. 2019;9:32357C32366. [Google Scholar] 45. Abou DS, Thiele NA, Gutsche NT, et al..Towards stable chelation of radium for biomedical applications with AZD3839 free base an 18-membered macrocyclic ligand. Chem Sci. 2021;12:3733C3742. [PMC free article] [PubMed] [Google Scholar] 46. Henriksen G, Hoff P, Larsen RH. Evaluation of potential chelating brokers for radium. Appl Radiat Isot. 2002;56:667C671. [PubMed] [Google Scholar] 47. Maguire WF, McDevitt MR, Smith-Jones PM, Scheinberg DA. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for a-particle radioimmunotherapy of malignancy. J Nucl Med. 2014;55:1492C1498. [PMC free article] [PubMed] [Google Scholar] 48. McDevitt MR, Ma D, Lai LT, et al..Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537C1540. [PubMed] [Google Scholar] 49. Miederer M, Henriksen G, Alke A, et al..Preclinical evaluation of the -particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Malignancy Res. 2008;14:3555C3561. [PubMed] [Google Scholar] 50. Graf F, Fahrer J, Maus S, et al..DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted.